{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "CTKB",
  "name": "Cytek Biosciences, Inc.",
  "url": "https://frontierpicks.com/dossiers/CTKB/",
  "json_url": "https://frontierpicks.com/dossiers/CTKB.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "archetype": {
    "code": "a7",
    "n": 7
  },
  "current_thesis": "Cytek Biosciences' revenue growth slowed to 2% in the third quarter and product sales fell, so the shares look more likely to lag the S&P 500 than lead it. Fourth-quarter revenue against the $208 million–$211 million outlook settles it.",
  "invalidation_trigger": "A daily close above $6.39, over the 52-week intraday high of $6.33 set on 2026-10-29, which would show the shares leading again. Quarterly revenue growth back at or above the 6% pace of the first half of 2026 would point the same way.",
  "catalyst_date": "2026-11-17",
  "portfolio": null,
  "pick": null,
  "themes": [
    "medtech-diagnostics"
  ],
  "tags": [],
  "sources": [],
  "caveats": [],
  "source_links": [
    {
      "title": "Cytek Biosciences, Inc. - Form 8-K - FY2026",
      "url": "https://www.sec.gov/Archives/edgar/data/0001831915/000119312526447300/d186499dex991.htm",
      "date": null
    },
    {
      "title": "Cytek Biosciences, Inc. - Form 10-Q - FY2026",
      "url": "https://www.sec.gov/Archives/edgar/data/0001831915/000162828026070259/ctkb-20260930.htm",
      "date": null
    },
    {
      "title": "Cytek beats on a gross margin surge but slowing growth and a fading EBITDA outlook leave a rallied stock little room for error",
      "url": "https://finviz.com/news/416344/cytek-beats-on-a-gross-margin-surge-but-slowing-growth-and-a-fading-ebitda-outlook-leave-a-rallied-stock-little-room-for-error",
      "date": null
    },
    {
      "title": "Cytek Biosciences reports third quarter 2026 financial results",
      "url": "https://finviz.com/news/415837/cytek-biosciences-reports-third-quarter-2026-financial-results",
      "date": null
    }
  ],
  "evidence": [
    {
      "claim": "Third-quarter 2026 revenue was $53.2 million, up 2% from $52.3 million; product revenue fell to $37.2 million from $38.1 million and service revenue rose to $16.1 million from $14.2 million.",
      "source": "Cytek Q3 2026 results release (8-K Exhibit 99.1)",
      "as_of": "2026-11-04"
    },
    {
      "claim": "Recurring revenue was $19.1 million in the quarter and 36% of trailing twelve-month revenue, up from 33% a year earlier.",
      "source": "Cytek Q3 2026 results release (8-K Exhibit 99.1)",
      "as_of": "2026-11-04"
    },
    {
      "claim": "GAAP gross margin was 59% versus 53% a year earlier; operating expenses rose 8% to $39.6 million; net loss was $6.1 million versus $5.5 million; adjusted EBITDA was $0.7 million versus $2.5 million.",
      "source": "Cytek Q3 2026 results release (8-K Exhibit 99.1)",
      "as_of": "2026-11-04"
    },
    {
      "claim": "Cytek narrowed 2026 revenue guidance to $208 million–$211 million from $207 million–$212 million; cash, restricted cash and marketable securities were $256.3 million at 2026-09-30, down from $262.0 million at 2026-06-30.",
      "source": "Cytek Q3 2026 results release (8-K Exhibit 99.1)",
      "as_of": "2026-11-04"
    },
    {
      "claim": "Installed base reached 4,073 Cytek instruments, with 140 units added in the third quarter.",
      "source": "Cytek Q3 2026 results release (8-K Exhibit 99.1)",
      "as_of": "2026-11-04"
    },
    {
      "claim": "U.S. revenue rose 12% to $30.4 million while Asia-Pacific revenue fell 25% and biopharma, distributor and contract research revenue fell about 17%.",
      "source": "Finviz analysis of Cytek Q3 2026 results",
      "as_of": "2026-11-05"
    },
    {
      "claim": "Q3 loss per share of $0.05 beat the $0.08 loss estimate and revenue of $53.229 million beat the $52.800 million estimate.",
      "source": "Benzinga earnings summary headline",
      "as_of": "2026-11-04"
    },
    {
      "claim": "Stephens & Co. maintained its Overweight rating on Cytek and raised its price target to $7.",
      "source": "Stephens & Co. rating headline",
      "as_of": "2026-11-10"
    }
  ],
  "view_changes": [],
  "frame": null,
  "filed_numbers": {
    "as_of": "2026-11-13",
    "sector": "Healthcare",
    "financials": {
      "status": "ok",
      "reason": null,
      "close_date": "2026-11-13",
      "latest_quarter": "2026-09-30",
      "figures": {
        "revenue": {
          "status": "ok",
          "quarters": [
            {
              "end": "2026-09-30",
              "filed": "2026-11-04",
              "restated": null,
              "value_musd": 53.2,
              "yoy_pct": 1.8
            },
            {
              "end": "2026-06-30",
              "filed": "2026-08-05",
              "restated": null,
              "value_musd": 48.1,
              "yoy_pct": 5.6
            },
            {
              "end": "2026-03-31",
              "filed": "2026-05-07",
              "restated": null,
              "value_musd": 44.1,
              "yoy_pct": 6.5
            },
            {
              "end": "2025-12-31",
              "filed": "2026-02-26",
              "restated": null,
              "value_musd": 62.1,
              "yoy_pct": 8.1
            },
            {
              "end": "2025-09-30",
              "filed": "2025-11-05",
              "restated": null,
              "value_musd": 52.3,
              "yoy_pct": 1.5
            },
            {
              "end": "2025-06-30",
              "filed": "2025-08-06",
              "restated": null,
              "value_musd": 45.6,
              "yoy_pct": -2.2
            }
          ]
        },
        "gross_margin": {
          "status": "ok",
          "quarters": [
            {
              "end": "2026-09-30",
              "filed": "2026-11-04",
              "restated": null,
              "pct": 58.6
            },
            {
              "end": "2026-06-30",
              "filed": "2026-08-05",
              "restated": null,
              "pct": 58.9
            },
            {
              "end": "2026-03-31",
              "filed": "2026-05-07",
              "restated": null,
              "pct": 48.2
            },
            {
              "end": "2025-12-31",
              "filed": "2026-02-26",
              "restated": null,
              "pct": 52.9
            },
            {
              "end": "2025-09-30",
              "filed": "2025-11-05",
              "restated": null,
              "pct": 52.7
            },
            {
              "end": "2025-06-30",
              "filed": "2025-08-06",
              "restated": null,
              "pct": 52.3
            }
          ]
        },
        "operating_margin": {
          "status": "ok",
          "quarters": [
            {
              "end": "2026-09-30",
              "filed": "2026-11-04",
              "restated": null,
              "pct": -15.8
            },
            {
              "end": "2026-06-30",
              "filed": "2026-08-05",
              "restated": null,
              "pct": -23.7
            },
            {
              "end": "2026-03-31",
              "filed": "2026-05-07",
              "restated": null,
              "pct": -41.8
            },
            {
              "end": "2025-12-31",
              "filed": "2026-02-26",
              "restated": null,
              "pct": -9
            },
            {
              "end": "2025-09-30",
              "filed": "2025-11-05",
              "restated": null,
              "pct": -17.6
            },
            {
              "end": "2025-06-30",
              "filed": "2025-08-06",
              "restated": null,
              "pct": -23.3
            }
          ]
        },
        "pretax_income": {
          "status": "ok",
          "end": "2025-12-31",
          "filed": "2026-02-26",
          "value_musd": -4
        },
        "net_income": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-04",
          "four_quarters_end": "2026-09-30",
          "value_musd": -6.1,
          "four_quarters_musd": -81.2
        },
        "operating_cash_flow": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-04",
          "first_end": "2025-12-31",
          "value_musd": -6.6
        },
        "capital_spending": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-04",
          "first_end": "2025-12-31",
          "value_musd": 6.9
        },
        "free_cash_flow": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-04",
          "first_end": "2025-12-31",
          "value_musd": -13.5
        },
        "diluted_share_change": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-04",
          "base_end": "2025-09-30",
          "pct": 2.2
        },
        "cash": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-04",
          "value_musd": 66.8
        },
        "debt": {
          "status": "not available"
        },
        "net_cash": {
          "status": "not available"
        },
        "deferred_revenue": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-04",
          "value_musd": 50.8,
          "yoy_pct": 10.2
        },
        "backlog": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-04",
          "value_musd": 49,
          "yoy_pct": 8.8
        },
        "receivables": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-04",
          "value_musd": 59.2
        },
        "inventory": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-04",
          "value_musd": 52.4
        },
        "equity": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-04",
          "value_musd": 321.4
        },
        "market_value": {
          "status": "ok",
          "close_date": "2026-11-13",
          "basis_end": "2026-10-31",
          "basis_filed": "2026-11-04",
          "value_musd": 763.8
        },
        "enterprise_value": {
          "status": "not available"
        },
        "ev_sales": {
          "status": "not available"
        },
        "ev_ebit": {
          "status": "not available"
        },
        "pe": {
          "status": "not meaningful"
        },
        "pb": {
          "status": "ok",
          "close_date": "2026-11-13",
          "basis_end": "2026-10-31",
          "basis_filed": "2026-11-04",
          "multiple": 2.4
        },
        "fcf_yield": {
          "status": "ok",
          "close_date": "2026-11-13",
          "basis_end": "2026-10-31",
          "basis_filed": "2026-11-04",
          "pct": -1.8
        }
      }
    },
    "short_interest": {
      "status": "ok",
      "settlement": "2026-10-15",
      "published": "2026-10-26",
      "short_pct_of_outstanding": 3.37,
      "days_to_cover": 2.7,
      "change_pct": -15.4
    },
    "insiders": {
      "status": "ok",
      "as_of": "2026-11-15",
      "windows": [
        {
          "days": 90,
          "status": "ok",
          "from": "2026-08-18",
          "bought_usd": 0,
          "sold_usd": 0,
          "bought_unpriced": 0,
          "sold_unpriced": 0
        },
        {
          "days": 365,
          "status": "ok",
          "from": "2025-11-16",
          "bought_usd": 0,
          "sold_usd": 0,
          "bought_unpriced": 0,
          "sold_unpriced": 0
        }
      ]
    }
  },
  "body_markdown": "## Current Thesis\nCytek Biosciences' revenue growth slowed to 2% in the third quarter of 2026, and product sales fell, so the shares look more likely to lag the S&P 500 than lead it. Fourth-quarter revenue against the $208 million–$211 million full-year outlook settles it.\n\nCytek reported third-quarter revenue of $53.2 million on 2026-11-04, up from $52.3 million a year earlier. Growth was 6% in the second quarter. The report beat analyst estimates on revenue ($53.229 million against $52.800 million) and on loss per share ($0.05 against $0.08), according to a Benzinga summary. The shares still closed at $5.40 on 2026-11-05, down from $5.88 on 2026-11-04, before recovering to $5.83 on 2026-11-06.\n\nMargin repair is the real improvement. Stephens & Co. kept its Overweight rating on 2026-11-10 and raised its price target to $7. The shares have risen 17.8% over three months, so the market already pays for margin gains and a U.S. academic recovery while product revenue and Asia-Pacific sales shrink.\n\n## Bull Case\n- **Gross margin is rising.** GAAP gross margin was 59% in the third quarter versus 53% a year earlier, and adjusted gross margin was 61% versus 55%, per the 2026-11-04 release.\n- **Recurring revenue keeps gaining share.** Recurring revenue was $19.1 million, or 36% of trailing twelve-month revenue versus 33% a year earlier. Service revenue rose to $16.1 million from $14.2 million.\n- **The U.S. is recovering.** A Finviz analysis of the report put U.S. revenue up 12% to $30.4 million. It also reported U.S. academic and government revenue up 38% and high-end analyzer revenue up more than 30%.\n- **The installed base keeps growing.** Cytek added 140 instruments in the quarter for a base of 4,073 as of 2026-09-30. Each adds a buyer for reagents and service.\n- **The balance sheet is large.** Cash, restricted cash and marketable securities were $256.3 million on 2026-09-30, against a quarterly net loss of $6.1 million.\n- **A covering analyst turned more positive.** Stephens & Co. raised its target to $7 on 2026-11-10 and kept an Overweight rating.\n\n## Bear Case\n- **Growth has slowed to 2%.** Third-quarter revenue rose 2% after 6% in both the first and second quarters. Product revenue fell to $37.2 million from $38.1 million.\n- **Asia-Pacific and biopharma are shrinking.** The Finviz analysis reported Asia-Pacific revenue down 25% and biopharma, distributor and contract research revenue down about 17%, after 22% growth in the second quarter.\n- **Profit is moving the wrong way.** Adjusted EBITDA was $0.7 million versus $2.5 million a year earlier. Operating expenses rose 8% to $39.6 million, and general and administrative costs rose 14% on litigation. The Finviz analysis reported that adjusted EBITDA guidance moved from positive to around break-even.\n- **The top of the outlook was cut.** Cytek narrowed 2026 revenue guidance to $208 million–$211 million from $207 million–$212 million on 2026-11-04. The Finviz analysis calculates that the range requires fourth-quarter revenue of roughly $62.5 million–$65.5 million, well above the third quarter's $53.2 million.\n- **Patent damages remain unresolved.** The 2026-08-21 jury awarded Beckman Coulter $20 million in lost profits and $36 million in royalties on one claim. Cytek has filed post-verdict motions and may appeal.\n\n## Setup & Price Structure\nThe shares closed at $5.76 on 2026-11-11. That is 9.0% below the 52-week intraday high of $6.33 set on 2026-10-29. The 50-day average of the adjusted closes was $5.46 and the 200-day average was $4.67 as of 2026-11-11, so the shares trade above both. The 52-week closing low was $3.35 on 2026-05-14. The three-month change was 17.8%, measured from the $4.89 close on 2026-08-13.\n\nAfter the 2026-11-04 report, the shares closed at $5.40 on 2026-11-05, then $5.83 on 2026-11-06, $5.89 on 2026-11-09, $5.79 on 2026-11-10 and $5.76 on 2026-11-11. The earlier October rally has not been regained: the high of $6.33 came a week before the report.\n\nSEC Form 4 filings dated 2026-08-20 show option exercises by the chief executive, chief financial officer, chief technology officer and three directors on 2026-08-18, with shares withheld for tax at $4.67. No open-market insider sales appear in the filings listed since then.\n\n## Catalyst Calendar\n\n- **2026-11-17:** Stephens Annual Investment Conference fireside chat with Cytek's chief executive and chief financial officer. Management can explain how the fourth quarter reaches the $208 million–$211 million full-year outlook after third-quarter revenue growth of 2%.\n- **~2027-03 (est.):** Fourth-quarter and full-year 2026 results (date not yet announced). Shows whether quarterly revenue growth returns to the 6% pace of the first half and whether the full-year outlook was met.\n\n## What Would Change Our Mind\n\nA daily close above $6.39, over the 52-week intraday high of $6.33 set on 2026-10-29, which would show the shares leading again. Quarterly revenue growth back at or above the 6% pace of the first half of 2026 would point the same way.\n\n## Correlation Notes\nCytek sells flow cytometry instruments, reagents, service and software to academic, government and pharmaceutical researchers. Its results track research-funding conditions, and the third quarter split on that line: U.S. academic and government demand rose while biopharma and Asia-Pacific demand fell. Research-tool peers such as 10x Genomics and Pacific Biosciences report on the same budgets, and weak results from either would bear on Cytek's instrument line. The shares trade on a US exchange.",
  "first_seen": "2026-11-10",
  "last_analyzed": "2026-11-12T04:20:45+00:00",
  "last_synthesized": "2026-11-12",
  "date_modified": "2026-11-12",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}